- Collaboration aims to combine Twist’s proprietary synthetic
antibody libraries and sophisticated bioinformatics expertise with
Sosei Heptares’ world-leading StaR® (stabilized receptor) platform
to generate novel antibody leads to disease-relevant GPCR
targets
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, and Sosei Group Corporation (“the
Company”; TSE: 4565), the world leader in GPCR-focused
structure-based drug design (SBDD) and development, announced a
strategic collaboration to discover therapeutic antibodies against
G protein-coupled receptors (GPCR) identified by Sosei
Heptares.
The collaboration will utilize Sosei Heptares’ fully
structurally enabled GPCR target proteins, isolated and stabilized
using its proprietary StaR® (stabilized receptor) platform
technology.
Twist will leverage its proprietary antibody libraries,
including two synthetic GPCR-focused antibody libraries, and apply
its sophisticated bioinformatics approaches.
Sosei Heptares will have exclusive, full global rights to
develop and commercialize any antibody leads identified and
directed to the targets of interest. Twist will be eligible for an
upfront payment, ongoing R&D costs and future payments based on
the achievement of predefined development milestones. No financial
terms are disclosed.
Miles Congreve, PhD, Chief Scientific Officer, Sosei
Heptares, said: "We are excited to partner with Twist
Biopharma, a division of Twist Bioscience, to combine our
world-leading GPCR-focused protein stabilization technologies with
Twist’s extensive libraries, as well as innovative discovery and
optimization technologies for therapeutic antibodies. GPCRs are
implicated in a wide variety of diseases where antibody
therapeutics are currently used. As a target class representing up
to 30% of current drug targets, very few GPCR-targeting antibodies
are approved drugs. This collaboration cements our ambition to
enhance our ability to expand and exploit the potential
opportunities generated by our GPCR platform, to create promising
GPCR-targeting antibody therapeutics for a range of diseases.”
“We are pleased to partner with Sosei Heptares, a recognized
leader in the stabilization of GPCR targets,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We
believe that by leveraging our target class specific GPCR antibody
library along with our discovery and optimization capabilities, we
will identify key antibody leads for further development by Sosei
Heptares.”
About Sosei Heptares
We are an international biopharmaceutical group focused on the
discovery and early development of new medicines originating from
our proprietary GPCR-targeted StaR® technology and structure-based
drug design platform capabilities. We are advancing a broad and
deep pipeline of novel medicines across multiple therapeutic areas,
including neurology, immunology, gastroenterology and inflammatory
diseases.
We have established partnerships with some of the world’s
leading pharmaceutical companies and multiple emerging technology
companies, including AbbVie, AstraZeneca, Biohaven, Genentech
(Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer and Takeda.
Sosei Heptares is headquartered in Tokyo, Japan with corporate and
R&D facilities in Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei
Group Corporation, which is listed on the Tokyo Stock Exchange
(ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks
of Sosei Group companies.
For more information, please visit https://soseiheptares.com/
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube:
@soseiheptaresco
About Twist Biopharma
By leveraging our unique ability to manufacture DNA at scale, we
can construct proprietary antibody libraries precisely designed to
match sequences that occur in the human body. This library of
libraries gives our partners an integral and unbiased resource for
antibody therapeutic discovery and optimization. This precise and
rational approach to library fabrication combined with
sophisticated bioinformatics and software expertise expedites
antibody discovery by decreasing risk, increasing speed, and
lowering the failure rate for antibody therapeutic development.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Forward-looking statements for Sosei Heptares
This press release contains forward-looking statements,
including statements about the discovery, development and
commercialization of products. Various risks may cause Sosei Group
Corporation’s actual results to differ materially from those
expressed or implied by the forward-looking statements, including:
adverse results in clinical development programs; failure to obtain
patent protection for inventions; commercial limitations imposed by
patents owned or controlled by third parties; dependence upon
strategic alliance partners to develop and commercialize products
and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from
development efforts; the requirement for substantial funding to
conduct research and development and to expand commercialization
activities; and product initiatives by competitors. As a result of
these factors, prospective investors are cautioned not to rely on
any forward-looking statements. We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Legal Notice Regarding Forward-Looking Statements for Twist
Bioscience
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation Twist’s ability to discover
novel therapeutic antibodies against multiple targets and to
achieve any of the clinical, regulatory or commercial milestones,
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; the retention
of employees of acquired companies and the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Annual Report Form 10-K filed with the Securities and Exchange
Commission on November 23, 2021 and subsequent filings with the
SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211216005408/en/
For Sosei Heptares:
Sosei Heptares – Media and Investor Relations Hironoshin
Nomura, SVP Investor Relations and Corporate Strategy +81 (0)3 6679
2178 | Hironoshin.Nomura@SoseiHeptares.com
Citigate Dewe Rogerson (for Japanese Media) Yas Fukuda
+81 (0)3 4360 9234, Yas.Fukuda@citigatedewerogerson.com
MEDiSTRAVA Consulting (for International Media) Mark
Swallow, David Dible, Eleanor Perkin +44 (0)20 7638 9571,
SoseiHeptares@medistrava.com
For Twist Bioscience:
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024